

Specialty Quantity Limit

Revtorpyk

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Revtorpyk	gedatolisib

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Revtorpyk (gedatolisib) 180 mg lyophilized powder in a single-dose vial	3 vials per 28 days

FDA-Recommended Dosing

180 mg intravenously once weekly on Days 1, 8, and 15 of a 28-day cycle.

Dose adjustments

May be required for adverse reactions:

- First dose reduction: 150 mg intravenously once weekly on Days 1, 8, and 15 of a 28-day cycle.

Reference number(s)
7543-H

- Second dose reduction: 130 mg intravenously once weekly on Days 1, 8, and 15 of a 28-day cycle.

References

1. Revtorpyk [package insert]. Minneapolis, MN: Celcuity Inc.; July 2026.